Correction to: Full population results from the core phase of CompLEEment-1, a phase 3b study of ribociclib plus letrozole as first-line therapy for advanced breast cancer in an expanded population (Breast Cancer Research and Treatment, (2021), 189, 3, (689-699), 10.1007/s10549-021-06334-0)

1. De Laurentiis, M.
2. Borstnar, S.
3. Campone, M.
4. Warner, E.
5. Bofill, J.S.
6. Jacot, W.
7. Dent, S.
8. Martin, M.
9. Ring, A.
10. Cottu, P.
11. Lu, J.
12. Ciruelos, E.
13. Azim, H.A.
14. Chatterjee, S.
15. Zhou, K.
16. Wu, J.
17. Menon-Singh, L.
18. Zamagni, C.

Export

Export

×

MLA

modern-language-association

APA

apa

Chicago

chicago-fullnote-bibliography

Harvard

harvard-cite-them-right

Vancouver

vancouver-author-date

---

RIS BibTex

Export

×

This document cannot be exported because it belongs to another portal.

Full text

lock_openFull text externo

DOI: 10.1007/S10549-021-06374-6 GOOGLE SCHOLAR lock_openOpen access editor

Sustainable development goals

• 

Data source: Scopus